The prospect of Canchi pharmaceutical industry is worrying many pharmacies under the shelf nimesulide

"Nimesulide" children fever drug adverse reaction events caused by the market shock is still continuing, the large pharmacy terminal has begun to "nimesulide particles." This for the "nimesulide" product sales gross profit accounted for the company's overall gross profit of more than 80% of the Canchi pharmaceutical industry (300086.　　SZ), the profit outlook is worrying. Yesterday, happy People's Congress pharmacy general Manager Secretary Yau Wen told the first financial daily, since February 15, the company through the Nanchang headquarters to Beijing, Shanghai and other subsidiaries of the quality management, will be nimesulide granules all the shelves. "Not only is the Canchi pharmaceutical industry's Rui Zhi Qing, other manufacturers of nimesulide particles have been all off the shelves, and have been linked to return."　　Yao Wen also said that, because the state Drug Administration has not announced the "nimesulide particles" adverse reaction of the results of the other contains "nimesulide" ingredients of the drug, the company although the implementation of the next frame processing, but has not been linked to return. Kyushu Tong da Pharmacy has also begun to recall the "nimesulide particles." Kyushu Tong da Pharmacy Shanghai Week Medicine store a person in charge said that the drug store has been discontinued "Rui Zhi Qing" nimesulide granules, "Just a few days ago headquarters issued a recall, now no longer external sales."　　The shop chief said. Chongqing, a large pharmaceutical circulation union-Heavy Pharmaceutical Co., Ltd. deputy general manager Ray also told reporters that recently received the Chongqing drug regulatory authorities, began to gradually recall the "nimesulide granules." "Last week has issued a notice to its various private pharmaceutical companies, from what channels from the same channel back."　　Ms. Lei said. Reporter visited some pharmacies in Shanghai is also difficult to find "nimesulide granules." Shanghai Lacey Pharmacy Tian Yi Country Pharmacy Jiangning Road store sales staff said the pharmacy never sold "Nimesulide granules."　　and Shanghai Huada Pharmacy Nanjingxilu Shop and Nine and Tang Kangding shop all said, because "nimesulide granules" There are larger security risks, pharmacies have never been sold.　　At present, although a few pharmacies in Shanghai are still selling "nimesulide granules", but no longer belong to the first line of drugs. Dalian Road Store, the people's big Pharmacy, said the pharmacy was sold "Nimesulide granules", but she also reminded reporters that pharmacies are currently sold in small quantities and must have a hospital prescription to buy.　　General Pediatric fever Medicine more recommended Tylenol and Merrill Lynch. And Sea King star Cao Bao Road shop, said that the shop does not sell Canchi pharmaceutical "Rui Zhi Qing" nimesulide granules, only Chongqing Hua Bang Pharmaceutical Co., Ltd. "RUI" brand Nemeshuligan suspension. "Ray" The specification said that the drug is attending rheumatoid arthritis and osteoarthritis, respiratory infection caused by fever symptoms.　　It also shows that the safety of children has not been established, so it is not recommended for children. The recall of the ' Nimesulide granule ' will reduce the short-term performance of the Canchi pharmaceutical industry and not rule out the use of the drug in the long term. One industry analyst told reporters. According to the Canchi pharmaceutical prospectus, the gross profit of Rui Zhi Qing in 2007, 2008 and 2009 accounted for 72.89%, 84.67% and 89.54 of gross profit in the same period respectively.%, the production and sales situation of Rui Zhi Qing basically determines the company's income and profitability level. "Despite the Canchi pharmaceutical's ' Rui Zhi Qing ' flagship level two hospital below the grassroots market, but its one or two-line city sales accounted for about 20%, and the future does not exclude rural and township market recalls."　　The analyst said. 18th, Canchi pharmaceutical industry closed at 66.10 Yuan, down 3.7%.